CJC-1295 (No DAC) + Ipamorelin – 5mg / 5mg [Growth Hormone Pulsing + Recovery]

CJC-1295 (No DAC) + Ipamorelin – 5mg / 5mg [Growth Hormone Pulsing + Recovery]

Supports natural growth hormone pulsatility by combining GHRH stimulation with a ghrelin-mimetic pathway for synergistic GH release.

This combination pairs CJC-1295 (No DAC), a short-acting growth hormone–releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue. Together, they are widely researched for their complementary mechanisms that stimulate endogenous growth hormone release while preserving natural pulsatile patterns.

Key Research Areas:
• Pulsatile growth hormone release
• IGF-1 signaling and endocrine research
• Recovery and tissue maintenance pathways
• Metabolic and body composition research

Unlike DAC-bound variants, CJC-1295 (No DAC) is researched for its shorter activity window, allowing precise timing of GH pulses. When combined with Ipamorelin, this pairing is commonly studied in laboratory environments focused on hormone dynamics, recovery signaling, and metabolic regulation.

Product Details:
• Compound: CJC-1295 (No DAC) + Ipamorelin
• Quantity: 5mg / 5mg
• Form: Lyophilized powder
• Packaging: Sterile sealed vial(s)
• Certificate of Analysis: Available

Storage & Handling:
Store in a cool, dry environment. Refrigeration recommended after reconstitution. Avoid repeated freeze–thaw cycles.

Disclaimer:
Information is provided for educational and research reference only and is not medical advice. Products are intended solely for laboratory research use and are not for human or veterinary consumption. These products have not been evaluated by Health Canada, the FDA, or any regulatory authority. Purchasers assume responsibility for lawful handling and use.